Manufacturing news briefs – stories you might have missed
FDA accepts Mesoblast’s responses Biotech company Mesoblast has announced that the United States Food and Drug Administration (FDA) has accepted Mesoblast’s Biologics License Application (BLA) resubmission for Ryoncil (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD). According to a statement, the FDA considers the resubmission to be a complete…
